Cytek Biosciences - bottom in?Potential bottoming out of this stock? Divergence on the RSI with a falling channel. Maybe worth watching for this institutional favourite.
−0.09USD
−12.15 MUSD
193.02 MUSD
118.77 M
About Cytek Biosciences, Inc.
Sector
Industry
CEO
Wen Bin Jiang
Website
Headquarters
Fremont
Employees (FY)
676
Founded
1992
FIGI
BBG00D36Q0Z7
Cytek Biosciences, Inc. is a life sciences technology company, which engages in the provision of cell analysis tools by leveraging novel technical approaches. Its products include Cytek Aurora CS, Cytek Aurora, Cytek Northern Lights, and Cytek NL-CLC. The company was founded by Wenbin Jiang and Ming Yan in 1992 and is headquartered in Fremont, CA.
$CTKB is giving a GREAT IPO LONG opportunity todayIPO intraday trading strategy idea
The share price is rising and gonna continue this trend today.
The demand for shares of the company still looks higher than the supply.
These and other conditions can cause a rise in the share price today.
So I opened a long position from $20,30;
stop-loss — $1
See all ideas
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of CTKB is 5.80 USD — it has decreased by 2.03% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Cytek Biosciences, Inc. stocks are traded under the ticker CTKB.
Cytek Biosciences, Inc. is going to release the next earnings report on May 8, 2024. Keep track of upcoming events with our Earnings Calendar.
CTKB stock is 3.95% volatile and has beta coefficient of 2.37. Check out the list of the most volatile stocks — is Cytek Biosciences, Inc. there?
One year price forecast for Cytek Biosciences, Inc. has a max estimate of 12.00 USD and a min estimate of 9.00 USD.
CTKB earnings for the last quarter are −0.01 USD per share, whereas the estimation was 0.02 USD resulting in a −135.07% surprise. The estimated earnings for the next quarter are 0.03 USD per share. See more details about Cytek Biosciences, Inc. earnings.
Cytek Biosciences, Inc. revenue for the last quarter amounts to 48.00 M USD despite the estimated figure of 55.48 M USD. In the next quarter revenue is expected to reach 56.58 M USD.
Yes, you can track Cytek Biosciences, Inc. financials in yearly and quarterly reports right on TradingView.
CTKB stock has fallen by 6.00% compared to the previous week, the month change is a 12.78% fall, over the last year Cytek Biosciences, Inc. has showed a 39.01% decrease.
CTKB net income for the last quarter is 5.50 M USD, while the quarter before that showed −6.46 M USD of net income which accounts for 185.24% change. Track more Cytek Biosciences, Inc. financial stats to get the full picture.
Today Cytek Biosciences, Inc. has the market capitalization of 758.78 M, it has decreased by 3.70% over the last week.
No, CTKB doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, CTKB shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Cytek Biosciences, Inc. stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 23, 2024, the company has 676.00 employees. See our rating of the largest employees — is Cytek Biosciences, Inc. on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Cytek Biosciences, Inc. technincal analysis shows the strong sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Cytek Biosciences, Inc. stock shows the sell signal. See more of Cytek Biosciences, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on Cytek Biosciences, Inc. future price: according to them, CTKB price has a max estimate of 12.00 USD and a min estimate of 9.00 USD. Read a more detailed Cytek Biosciences, Inc. forecast: see what analysts think of Cytek Biosciences, Inc. and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Cytek Biosciences, Inc. EBITDA is −17.94 M USD, and current EBITDA margin is −8.87%. See more stats in Cytek Biosciences, Inc. financial statements.